26 May, 2017
Sarepta Therapeutics, Inc. (SRPT) has the market capitalization of $1.83 Billion. The Qvt Financial Lp holds 212,776 shares with $5.84 million value, down from 496,434 last quarter. Institutional investors own 76.75% of the company's stock. CPE stock price climbed 9.38% over the past year, yielding a negative weighted alpha of -1.3 percent. It has underperformed by 5.22% the S&P500. The Connecticut-based Cubist Systematic Strategies Lc has invested 0.01% in Sarepta Therapeutics Inc (NASDAQ:SRPT). New York State Common Retirement Fund now owns 47,059 shares of the biotechnology company's stock worth $2,890,000 after buying an additional 2,359 shares during the period. The company reported EPS of $-0.71, below the consensus estimate calling for EPS of $-0.27 - a negative surprise of -166.52%. Sarepta Therapeutics has $91 highest and $27 lowest target. (SRPT) is 1.5 while the analysts predicted the EPS of the stock to be -0.32 suggesting the company fell short of the analysts' expectations. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 96.82% since May 25, 2016 and is uptrending.
Investors sentiment decreased to 0.81 in 2016 Q4.
Whereas they predicted High and Low Earnings Estimate as $-0.59 and $-1.2 respectively.
Several institutional investors have recently bought and sold shares of the company. Royal Bancorp Of Canada reported 6,147 shares. Elk Creek Prns Limited Liability reported 316,463 shares. Northern reported 580,523 shares. Envestnet Asset has 575 shares for 0% of their portfolio. North Star Mgmt owns 735 shares. Point72 Asset Management Limited Partnership owns 1.37 million shares or 0.26% of their U.S. portfolio. Analysts forecast EPS of $-0.91, up exactly $0.43 or 32.09 % from 2014's $-1.34 EPS. Float is the number of shares available for trading of a particular stock. Dreman Value Management L L C invested in 0.34% or 18,901 shares. It also upped Continental Resources Inc (NYSE:CLR) stake by 254,500 shares and now owns 1.02M shares. Plante Moran Fincl Advsrs Llc holds 0.18% of its portfolio in Marathon Oil Corporation (NYSE:MRO) for 16,893 shares.
Among 13 analysts covering Marriott International (NASDAQ:MAR), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 80% are positive. MPLX LP had 34 analyst reports since October 20, 2015 according to SRatingsIntel. The firm has "Buy" rating by Evercore given on Monday, September 7. Sarepta Therapeutics presently has a consensus rating of Buy and an average price target of $59.95. Needham maintained the stock with "Buy" rating in Friday, October 2 report. The rating was maintained by Morgan Stanley with "Equal-Weight" on Wednesday, January 4. The rating was upgraded by Leerink Swann to "Outperform" on Thursday, March 2. The firm has "Neutral" rating by Suntrust Robinson given on Friday, August 7. Piper Jaffray maintained it with "Overweight" rating and $51 target in Saturday, September 5 report. Floating stock is calculated by subtracting closely-held shares and restricted stock from a firm's total outstanding shares. The rating was downgraded by Oppenheimer to "Perform" on Tuesday, April 26.
The company is scheduled to announce its next quarterly financial results on 18/07/2017 after the market close.
11/20/2013 - CRT Capital began new coverage on Sorrento Therapeutics, Inc. giving the company a "buy" rating.
Since February 27, 2017, it had 0 insider purchases, and 5 selling transactions for $5.16 million activity. (FB) . Average true range (ATR-14) of the company is at 2.02. The insider HILL CHARLES H sold 36,000 shares worth $1.23 million. It also reduced its holding in Ituran Location And Control (NASDAQ:ITRN) by 150,035 shares in the quarter, leaving it with 306,633 shares, and cut its stake in Nice Ltd (NASDAQ:NICE). Its down 0.45, from 1.52 in 2016Q3. RBC Capital Markets maintained the shares of SRPT in report on Friday, December 16 with "Outperform" rating. 60 funds opened positions while 160 raised stakes. Perceptive Advsr Ltd Liability has invested 5.41% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Blackrock Japan Company Limited holds 791 shares.
Many analysts have provided their estimated foresights on Sarepta Therapeutics, Inc. Massachusetts-based Rhumbline Advisers has invested 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Baxter Bros Inc holds 0.17% or 6,227 shares in its portfolio. Smith Asset Grp Incorporated Ltd Partnership invested in 0.01% or 9,260 shares. Sarepta Therapeutics, Inc. (SRPT) has made its way to a 12-month gain of 84.61%. Sarepta Therapeutics Inc (NASDAQ:SRPT)'s price sits 1.17% above from its 50-day moving average of $32.66 and -7.50% away from the stock's 200-day moving average which is $32.35. Natixis has 365,208 shares for 0.31% of their portfolio.
